<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022282</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068801</org_study_id>
    <secondary_id>AETERNA-AE-MM-00-02</secondary_id>
    <nct_id>NCT00022282</nct_id>
  </id_info>
  <brief_title>AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Neovastat (AE-941) in Refractory and Early Relapse Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <brief_summary>
    <textblock>
      RATIONALE: AE-941 may help to slow the growth of multiple myeloma.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of neovastat in treating patients who have&#xD;
      relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the confirmed tumor response rate in patients with early relapse or refractory&#xD;
           multiple myeloma treated with AE-941 (Neovastat).&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Evaluate the time to progression in patients treated with this drug.&#xD;
&#xD;
        -  Evaluate the duration of tumor response (partial response, response, and complete&#xD;
           response) in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label study.&#xD;
&#xD;
      Patients receive oral AE-941 (Neovastat) twice daily.&#xD;
&#xD;
      Patients are followed every 4 weeks until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 125 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>shark cartilage extract AE-941</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma (MM) according to the Durie and Salmon criteria&#xD;
&#xD;
          -  Refractory to or in early relapse after standard chemotherapy with or without stem&#xD;
             cell transplantation&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Quantifiable IgM, IgG, or IgA paraprotein in serum AND/OR&#xD;
&#xD;
               -  Bence-Jones protein in urine&#xD;
&#xD;
          -  No plasma cell leukemia (more than 20% plasma cells in peripheral blood and an&#xD;
             absolute plasma cell count of at least 2,000/mm3)&#xD;
&#xD;
          -  No nonsecretory MM&#xD;
&#xD;
          -  No spinal cord compression&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  No clinical symptoms of hyperviscosity&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times upper limit of normal&#xD;
&#xD;
          -  Calcium no greater than 11 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except basal cell carcinoma of the&#xD;
             skin or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No severe allergy to fish or seafood&#xD;
&#xD;
          -  No medical condition that would interfere with intake and/or absorption of study&#xD;
             medication (e.g., gastrectomy or major intestinal resection)&#xD;
&#xD;
          -  No significant medical or psychiatric condition that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use adequate contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior history of treatment with thalidomide for more than 14 days duration&#xD;
&#xD;
          -  At least 4 weeks since prior biological therapy for MM&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy for MM&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior steroid therapy for MM&#xD;
&#xD;
          -  No prednisone maintenance therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent palliative or curative radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 28 days since other prior shark cartilage products&#xD;
&#xD;
          -  At least 28 days since other prior experimental therapeutic agents&#xD;
&#xD;
          -  Concurrent monthly bisphosphonate (pamidronates) infusions allowed&#xD;
&#xD;
          -  No other concurrent anticancer treatment&#xD;
&#xD;
          -  No other concurrent shark cartilage products&#xD;
&#xD;
          -  No other concurrent therapies for MM&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>October 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2003</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

